Find information on thousands of medical conditions and prescription drugs.

Coreg

Carvedilol (Coreg®) is a non-selective beta blocker indicated in the treatment of mild to moderate congestive heart failure (CHF). In addition to blocking both β1 and β2 type adrenoreceptors, carvedilol also displays α1-adrenergic antagonism as well, which confers the added benefit of reducing blood pressure through vasodilation. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

More importantly, carvedilol also has a minimal potential for "inverse agonism", or the deactivation of an activated receptor. This is important to CHF sufferers since inverse agonism causes negative chronotropic and inotropic effects. Essentially, carvedilol does not decrease the rate or strength of the hearts contractions as much as other beta blocking medications. CHF often significantly reduces how well the heart pumps, so any medication that further weakens the rate or strength of contractions is undesireable, therefore making carvedilol a better treatment than a beta blocker with stronger inverse agonism (such as propranolol).

On January 10, 2006, GlaxoSmithKline announced to pharmicists and physicans that there will be a limited availability of Coreg. This is due to documentation procedures with the manufacturer. It is not known when will Coreg will become broadly available. Patients who are taking Coreg should consult their healthcare professional about what actions they should take due to the shortage.

Read more at Wikipedia.org


[List your site here Free!]


'Broken' branded pipeline opens new generics pathways
From Drug Store News, 9/26/05 by James Frederick

SAN DIEGO -- A slowdown in sales growth continues to plague the branded pharmaceutical industry, according to an industry expert from IMS Health, leaving the field open for new inroads by generic drug competitors.

Describing pharmaceuticals as a "cyclical business," IMS vice president of industry relations Doug Long noted that a general weakening in sales tot branded drugs had opened the door wider for generic competition.

"When it was very strong, you had a lot of innovation," he said. "And now that it's weak on a dollar basis, what you see is many patent expirations, and that gives generics companies an opportunity to compete."

That competition, he added, is based on price discounting. "The way they compete is on price, and since there are many more generics companies in the game today, the price is going lower and lower and lower.

"That necessitates the branded companies that lost the patent to go back and replace those lost products with new ones," Long noted. "That's the part that's broken right now: They can't replace what they lost with new products in this environment. It's getting tougher, and the FDA is getting more cautious at the same time.

"That means it will be even more expensive to bring drugs to market--and longer. And there will be more burdens after the product is launched until the marketing is available. So it's going to be difficult, and it will be less likely to see as many new products entering the market."

Last year, on the other hand, "was a pretty good year" for branded drug makers, said Long, with 31 new molecular entities approved by the Food and Drug Administration. "Right now, we have 10 [this year]," he noted.

Several trends have put the brakes on growth momentum for branded pharmaceuticals, according to the IMS official. Among them: moderating prices for drugs as cost pressures continue to mount for government and private health plan payers; a delay in new product approvals from the FDA; a general, if temporary, slowdown in prescription utilization; and a weak flu season. Also slowing sales growth is the continued shift of prescription drugs to OTC status and the highly publicized and controversial withdrawals of blockbuster medications like Vioxx over safety concerns.

Ironically, more aggressive efforts by payers and pharmacies to shift patients to generics also have stymied branded pharmaceutical sales growth, said Long.

JAMES FREDERICK

CATEGORY SPECIALIST

COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group

Return to Coreg
Home Contact Resources Exchange Links ebay